一种新的麻疹药物NV-387在测试中使存活率提高了130%,在美国爆发1 600多例病例时,现在有资格紧急使用。 A new measles drug, NV-387, boosted survival by 130% in tests and is now eligible for emergency use amid a U.S. outbreak of over 1,600 cases.

NanoViricides， Inc. 宣布其实验药物 NV-387 在人源化动物模型中显示出对麻疹的强大有效性，将生存时间延长了 130%，且无毒性，现在有资格在美国麻疹疫情超过 1,600 例的情况下紧急使用——这是 30 多年来的最高水平。 NanoViricides, Inc. announced its experimental drug NV-387 showed strong effectiveness against measles in humanized animal models, increasing survival time by 130% with no toxicity, and is now eligible for emergency use amid a U.S. measles outbreak exceeding 1,600 cases—the highest in over 30 years. 该药物作为可溶解的口服口服口服口服口服口服药,按照美国GMP标准制造,已完成第一阶段试验,没有不良影响。 The drug, administered as dissolvable oral gummies and manufactured under U.S. GMP standards, has completed Phase I trials without adverse effects. 它正在开发为针对麻疹,RSV,流感和其他呼吸系统病毒的广泛抗病毒药物,该公司根据FDA指导方针支持医生主导的紧急使用应用. It is being developed as a broad-spectrum antiviral targeting measles, RSV, influenza, and other respiratory viruses, with the company supporting physician-led emergency use applications under FDA guidelines.